Supplemental Material2 - Supplemental material for Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease Luisa Guidi Daniela Pugliese Tommaso Panici Tonucci Lorenzo Bertani Francesco Costa Giuseppe Privitera Barbara Tolusso Clara Di Mario Eleonora Albano Gherardo Tapete Elisa Gremese Alfredo Papa Antonio Gasbarrini Gian Ludovico Rapaccini Alessandro Armuzzi 10.25384/SAGE.9767369.v1 https://sage.figshare.com/articles/journal_contribution/Supplemental_Material2_-_Supplemental_material_for_Early_vedolizumab_trough_levels_predict_treatment_persistence_over_the_first_year_in_inflammatory_bowel_disease/9767369 <p>Supplemental material, Supplemental Material2 for Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease by Luisa Guidi, Daniela Pugliese, Tommaso Panici Tonucci, Lorenzo Bertani, Francesco Costa, Giuseppe Privitera, Barbara Tolusso, Clara Di Mario, Eleonora Albano, Gherardo Tapete, Elisa Gremese, Alfredo Papa, Antonio Gasbarrini, Gian Ludovico Rapaccini and Alessandro Armuzzi in United European Gastroenterology Journal</p> 2019-09-04 12:08:15 Vedolizumab therapeutic drug monitoring Crohn’s disease ulcerative colitis